Where the money went: management itemizes the period's spending into named growth uses tied to business already live
The model's full reasoning — Q2 2023 call → NOWe need to determine if management gives a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and ties those to already-real business. The transcript includes financial results from Bart Van Rhijn. He mentions R&D expenses increased due to clinical trial development priorities, specifically NANORAY-312. SG&A increased due to financial advisor fees. He also mentions the Janssen deal and cash runway. However, does he itemize specific growth-directed uses? He says R&D expenses increased by EUR1.5 million due to advancing clinical trial development priorities, specifically the global Phase 3 registrational trial NANORAY-312. That is a named use. But is it tied to already-real business? The trial is ongoing, patients are being recruited, but is that "already-real business"? The trial is a clinical trial, not revenue-generating. The question asks for "orders, customers, contracts, volumes, openings, or activity already arriving or already committed now". The trial is an activity already underway, but it's not business in the sense of revenue. The company is spending on clinical trials to develop a product. The spending is for future potential, not current revenue. The question specifically says "so that the spending reads as the visible cost of growth already underway rather than as hope, waste, or defense." The trial is growth underway, but is it tied to already-real business? The trial is a committed activity, but it's not generating revenue. The question says "business that is ALREADY REAL — actual orders, customers, contracts, volumes, openings, or activity already arriving or already committed now". The clinical trial is an activity already committed, but it's not business in the sense of commercial activity. However, the question allows "activity already arriving or already committed now". The trial is committed. But the spending is for R&D, not for fulfilling orders. The question is about whether management itemizes spending and ties it to real business. Here, management mentions the Janssen deal, which is a contract. The $30 million upfront is received. That is real business. But the spending is not tied to that. The spending is on clinical trials. The clinical trials are for future regulatory approval. The question asks if the spending is the cost of growth already underway.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
AES · Q1 2024 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES Management itemizes the period’s spending in two places. - Utilities: “our Q1 investment was up nearly 100% from last year, as a result of the new rate structures and investing to improve system resilience and customer experience.” - Renewables: “we have also added almost 600 meg awatts of new projects to our operating portfolio” and “we remain fully on track to add a total of 3.6 gigawatts of new capacity this year” with “92% of the major equipment already on site” for 2024 projects. Both uses are explicitly tied to already-signed backlog ( 12.7 GW signed contracts, 1.
GTES · Q4 2021 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES The transcript shows management itemizing specific growth-directed uses—targeted incremental capacity investments, material science, and innovation—explicitly tied to already-real business: record backlog, book-to-build above 1, strong order rates, and committed wins (e.g., Gogoro, EV platform). These are framed as 2021 spending that consumed profitability and cash flow in Q4, directly supporting demand already arriving rather than future hope. While some operational headwinds (COVID, materials) are noted, the capacity investments are presented as the visible cost of growth underway.
DAN · Q1 2017 → YESThe question is about whether management gives a concrete accounting of where the period's money and effort went, specifically for growth-directed uses tied to already real business. YES Management itemizes concrete uses of the period’s cash and effort: higher capital spending to convert the $175 million backlog (Super Duty, Toyota HiLux, Jeep Wrangler readiness), the $25 million trade-payable settlement tied to the USM acquisition that is already supplying Dana, the Brevini integration costs 8 % organic growth plus aftermarket recovery, and the start-up costs of the new Toledo facility and Hungary gear plant that are supporting committed customer programs already in motion.